Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection

Low patient compliance due to the development of adverse events in the form of antibiotic-associated diarrhea (AAD) is considered as the main reason for the failure of the eradication of optimized anti-Helicobacter therapy regimens. A key mechanism for the development of AAD is to reduce the number and species diversity of bacteria that form butyric acid. Aim. The purpose of this study was to study the comparative effect on the clinical effectiveness of eradication therapy (ET) of Helicobacter pylori infection and metabolic changes in the colon microbiota of additional inclusion in the optimized treatment regimen of the combined prebiotic Zakofalk (inulin + butyrate) with probiotics (lacto- and bifidobacteria in an amount of at least 1017 СFU). Materials and methods. 120 patients with chronic gastroduodenal diseases and infected H. pylori were еxamined. A comparative analysis of the effect of a combined prebiotic and lacto-bifid-containing probiotics on improving the effectiveness of the optimized ET scheme and improving its tolerability, as well as on the quantitative and qualitative content of short-chain fatty acids (SFA) in feces. The success of eradication was controlled by a 13C urease breath test. Results. According to the results of the study in randomized groups of patients, an excellent percentage of eradication (95%) was achieved in patients who performed ET with the addition of the prebiotic Zakofalk. In the same group of patients, there was an increase in the absolute content of SFA and a significant increase in the concentration of butyric acid. In the group of patients who received ET with the addition of probiotics, an acceptable level of eradication was achieved (85.7%), but no changes in SFA were found indicating an increase in the number or activity of the butyrate-producing flora. Patients who performed ET without the addition of pre-probiotics did not achieve the target percentage of successful eradication (83.3%), and a significant quantitative decrease in SFA was found with a significant decrease in the proportion of butyric acid. Conclusion. The inclusion of Zakofalk in the ET scheme, in comparison with probiotics, significantly increases the probability of successful eradication, more effectively restores the metabolic potential of the microbiota, and prevents the development of AAD.

COMPLEX THERAPY OF GASTRODUODENITIS WITH THE SYNDROME OF EXCESSIVE BACTERIAL GROWTH

The aim of the study was to evaluate the clinical efficacy and safety of the probiotic containing Lactobacillus acidophilus and Kefir grains (Acipol®) in the complex therapy of chronic gastroduodenal diseases with a syndrome of excessive bacterial growth in children aged 6 to 17 years.We observed 43 children with chronic gastroduodenal diseases associated with Helicobacter pylori infection, accompanied by a syndrome of excessive bacterial growth. Patients were divided into 2 groups: 1 group comprised 28 children who received Acipol 2 weeks on a background of standard therapy, and 2 group (15 people) received standard therapy without Acipol. All children of both groups were assessed pain index, dyspeptic index, hydrogen respiratory test with lactulose, quantitative PCR in feces before treatment, after 2 weeks, after 6 weeks.After 2 weeks, there was a significant decrease in pain index and dyspeptic index in group 1, by 6 weeks this decline continued. The hydrogen breathing test with lactulose, conducted after 2 weeks, became negative in group 1 in 13 children (46%), and was preserved in 15 (54%). The same result was noted after 6 weeks. That is, elimination of the syndrome of excessive bacterial growth was achieved in 43% of children against the background of Acipol.